Get started
Author

Susan Cantin

ORCID: 0000-0002-8674-8284
Observed ORCID: 0000-0002-8674-8284
OpenAlex ID: A5062785500
Treatment with HC-070, a potent inhibitor of TRPC4 and TRPC5, leads to anxiolytic and antidepressant effects in mice
2018 · Stefan Just, Bertrand L. Chenard, et al. · PLoS ONE · 137
PDF
Systemic nano-delivery of low-dose STING agonist targeted to CD103+ dendritic cells for cancer immunotherapy
2022 · Aatman S. Doshi, Susan Cantin, et al. · Journal of Controlled Release · 65
STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1
2020 · Theresa A. Proia, Maneesh Singh, et al. · Clinical Cancer Research · 63
PDF
XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
2023 · Ekta Patel, Natalia V. Malkova, et al. · Molecular Cancer Therapeutics · 19
PDF
Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners
2023 · Aatman S. Doshi, Susan Cantin, et al. · Molecular Cancer Therapeutics · 16
Discovery of (2R,4R)-4-((S)-2-Amino-3-methylbutanamido)-2-(4-boronobutyl)pyrrolidine-2-carboxylic Acid (AZD0011), an Actively Transported Prodrug of a Potent Arginase Inhibitor to Treat Cancer
2024 · Scott N. Mlynarski, Brian M. Aquila, et al. · Journal of Medicinal Chemistry · 8
Abstract 4523: Inhibition of arginase in combination with anti-PDL1 leads to increased infiltration and activation of CD8+ T cells, NK cells, and CD103+ dendritic cells in mouse syngeneic tumor models
2020 · Alwin Schuller, Aatman Doshi, et al. · Cancer Research · 4
Abstract 1664: Inhibition of arginase in combination with radiation therapy shows increased immune-activation and anti-tumor activity in syngeneic tumor models
2021 · Alwin Schuller, Aatman Doshi, et al. · Cancer Research · 2
Supplementary Table S2 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
2026 · Ekta Patel, Natalia V. Malkova, et al.
Supplementary Figure S7 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
2026 · Ekta Patel, Natalia V. Malkova, et al.
Supplementary Figure S3 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
2026 · Ekta Patel, Natalia V. Malkova, et al.
Supplementary Figure S6 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
2026 · Ekta Patel, Natalia V. Malkova, et al.
Supplementary Table S3 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
2026 · Ekta Patel, Natalia V. Malkova, et al.
Supplementary Figure S5 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
2026 · Ekta Patel, Natalia V. Malkova, et al.
Supplementary Table S1 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
2026 · Ekta Patel, Natalia V. Malkova, et al.
Supplementary Figure S2 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
2026 · Ekta Patel, Natalia V. Malkova, et al.
Supplementary Figure S1 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
2026 · Ekta Patel, Natalia V. Malkova, et al.
Supplementary Figure S4 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
2026 · Ekta Patel, Natalia V. Malkova, et al.
Effects of acute inhibition of solute carrier family 6 member 19 on plasma and brain amino acid levels and on neurotransmitters in a mouse model of phenylketonuria
2026 · Heike Wobst, Ryan Philbin, et al. · Molecular Genetics and Metabolism
Supplementary Figure 2 from Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners
2025 · Aatman S. Doshi, Susan Cantin, et al.
Supplementary Table 1 from Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners
2025 · Aatman S. Doshi, Susan Cantin, et al.
Supplementary Figure 4 from Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners
2025 · Aatman S. Doshi, Susan Cantin, et al.
Supplementary Figure 3 from Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners
2025 · Aatman S. Doshi, Susan Cantin, et al.
Supplementary Figure 5 from Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners
2025 · Aatman S. Doshi, Susan Cantin, et al.
Supplementary Figure 1 from Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners
2025 · Aatman S. Doshi, Susan Cantin, et al.
Works count: 96
Citation count: 314
H-index: 6
I10-index: 5
Year
Topic
Type